|
US3887699A
(en)
|
1969-03-24 |
1975-06-03 |
Seymour Yolles |
Biodegradable polymeric article for dispensing drugs
|
|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
|
PH19942A
(en)
|
1980-11-18 |
1986-08-14 |
Sintex Inc |
Microencapsulation of water soluble polypeptides
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
US4452775A
(en)
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
US5407686A
(en)
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
CA2150803C
(en)
|
1992-12-02 |
2006-01-31 |
Henry Auer |
Controlled release growth hormone containing microspheres
|
|
WO1995000645A2
(en)
|
1993-06-21 |
1995-01-05 |
Genentech, Inc. |
Process for producing relaxin
|
|
US6869930B1
(en)
|
1993-09-17 |
2005-03-22 |
Novo Nordisk A/S |
Acylated insulin
|
|
EP1132404A3
(en)
|
1993-09-17 |
2002-03-27 |
Novo Nordisk A/S |
Acylated insulin
|
|
US6011007A
(en)
|
1993-09-17 |
2000-01-04 |
Novo Nordisk A/S |
Acylated insulin
|
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
|
PT779806E
(pt)
|
1994-09-09 |
2001-02-28 |
Takeda Chemical Industries Ltd |
Preparacao de libertacao sustentada contendo um sal metalico de um peptido
|
|
EP0817620B1
(en)
|
1995-03-28 |
2002-01-30 |
Fidia Advanced Biopolymers, S.R.L. |
Nanospheres comprising a biocompatible polysaccharide
|
|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
TW457240B
(en)
|
1995-04-20 |
2001-10-01 |
Janssen Pharmaceutica Nv |
Novel triazolones as apolipoprotein-B synthesis inhibitors
|
|
US5811395A
(en)
|
1995-06-07 |
1998-09-22 |
Medical University Of South Carolina |
Relaxin analogs and derivatives methods and uses thereof
|
|
US5911997A
(en)
|
1995-06-07 |
1999-06-15 |
Connetics Corporation |
Relaxin-like factor and methods and uses thereof
|
|
PT831787E
(pt)
|
1995-06-07 |
2002-02-28 |
Alkermes Inc |
Composicao para libertacao sustentada da hormona de crescimento humano
|
|
ZA965368B
(en)
|
1995-07-14 |
1997-01-14 |
Novo Nordisk As |
A pharmaceutical formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
|
US5612051A
(en)
|
1995-11-17 |
1997-03-18 |
Yue; Samuel K. |
Method of treating involuntary muscle dysfunction with relaxin hormone
|
|
US5866538A
(en)
|
1996-06-20 |
1999-02-02 |
Novo Nordisk A/S |
Insulin preparations containing NaCl
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
|
DE19822820A1
(de)
|
1998-05-20 |
1999-11-25 |
Biotechnolog Forschung Gmbh |
Pharmazeutisches Präparat zur Wundbehandlung
|
|
US6566329B1
(en)
|
1999-06-28 |
2003-05-20 |
Novo Nordisk A/S |
Freeze-dried preparation of human growth hormone
|
|
CZ20033182A3
(cs)
|
2001-05-21 |
2004-09-15 |
Nektar Therapeutics |
Inzulínový prostředek a způsob podávání inzulínu
|
|
AU2003243316A1
(en)
|
2002-05-24 |
2003-12-12 |
Nps Allelix Corp. |
Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
|
|
WO2003103572A2
(en)
*
|
2002-06-04 |
2003-12-18 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
|
US20050176108A1
(en)
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
US7919118B2
(en)
|
2003-05-12 |
2011-04-05 |
Affymax, Inc. |
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
|
|
US20060183667A1
(en)
|
2003-07-11 |
2006-08-17 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
|
BR122019021416A2
(enExample)
|
2003-09-19 |
2019-12-21 |
|
|
|
US7202332B2
(en)
|
2004-05-27 |
2007-04-10 |
New York University |
Methods for preparing internally constrained peptides and peptidomimetics
|
|
WO2006066258A2
(en)
|
2004-12-17 |
2006-06-22 |
Neose Technologies, Inc. |
Lipoconjugation of peptides
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
UA95235C2
(en)
|
2005-05-04 |
2011-07-25 |
Зииланд Фарма А/С |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
EA200801174A1
(ru)
|
2005-10-24 |
2009-02-27 |
Сентокор, Инк. |
Антитела-миметики glp-2, полипептиды, композиции, способы и применения
|
|
CA2638800A1
(en)
|
2006-02-22 |
2007-09-07 |
Merck & Co., Inc. |
Oxyntomodulin derivatives
|
|
US20080305519A1
(en)
|
2006-02-23 |
2008-12-11 |
Qing Lin |
Biochemical method for specific protein labeling
|
|
WO2007109035A2
(en)
|
2006-03-16 |
2007-09-27 |
The Scripps Research Institute |
Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
|
|
MX2008012055A
(es)
|
2006-03-20 |
2008-10-02 |
Merck & Co Inc |
Agonistas del receptor de neuromedina u y usos de los mismos.
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
JP2009534423A
(ja)
|
2006-04-20 |
2009-09-24 |
アムジェン インコーポレイテッド |
Ｇｌｐ−１化合物
|
|
WO2007139941A2
(en)
|
2006-05-26 |
2007-12-06 |
Amylin Pharmaceuticals, Inc. |
Composition and methods for treatment of congestive heart failure
|
|
JP5290177B2
(ja)
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
|
|
EP2069502B1
(en)
|
2006-09-27 |
2014-02-26 |
Novo Nordisk A/S |
Method for making maturated insulin polypeptides
|
|
WO2008057298A2
(en)
|
2006-10-27 |
2008-05-15 |
Wei-Chiang Shen |
Lipidized interferon and uses thereof
|
|
BRPI0720306A2
(pt)
|
2006-12-14 |
2014-02-04 |
Aileron Therapeutics Inc |
Sistemas de macrociclização da bis-sufidrila
|
|
US7981998B2
(en)
|
2006-12-14 |
2011-07-19 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
ES2649941T3
(es)
|
2007-02-23 |
2018-01-16 |
Aileron Therapeutics, Inc. |
Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
JP2010530433A
(ja)
|
2007-06-20 |
2010-09-09 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ａｐｏａ−１ペプチド模倣体
|
|
DE112009000300T5
(de)
|
2008-02-08 |
2011-01-20 |
Aileron Therapeutics, Inc., Cambridge |
Therapeutische Peptidomimetische Makrocyclen
|
|
US20110144303A1
(en)
|
2008-04-08 |
2011-06-16 |
Aileron Therapeutics, Inc. |
Biologically Active Peptidomimetic Macrocycles
|
|
EP2310407A4
(en)
|
2008-04-08 |
2011-09-14 |
Aileron Therapeutics Inc |
BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
|
|
CN102105159B
(zh)
|
2008-06-17 |
2015-07-08 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
|
US8586707B2
(en)
|
2008-09-16 |
2013-11-19 |
The Research Foundation Of State University Of New York |
Stapled peptides and method of synthesis
|
|
CN102203126A
(zh)
|
2008-09-22 |
2011-09-28 |
爱勒让治疗公司 |
用于制备纯化的多肽组合物的方法
|
|
BRPI0920889A2
(pt)
|
2008-09-22 |
2017-10-10 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos.
|
|
CA2737922A1
(en)
|
2008-09-22 |
2010-03-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
BRPI0920899A2
(pt)
|
2008-11-24 |
2016-04-26 |
Aileron Therapeutics Inc |
macrociclos peptidomiméticos com propriedades melhoradas
|
|
US9175047B2
(en)
|
2009-01-14 |
2015-11-03 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
CN104147611A
(zh)
|
2009-09-30 |
2014-11-19 |
葛兰素集团有限公司 |
具有延长的半衰期的药物融合体和缀合物
|
|
US20110223149A1
(en)
|
2009-10-14 |
2011-09-15 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
US20110243943A1
(en)
|
2010-04-02 |
2011-10-06 |
Athena Discovery, Inc. |
Treatment using relaxin-fusion proteins with extended in vivo half-lives
|
|
CN103097413A
(zh)
|
2010-07-09 |
2013-05-08 |
Jv生物公司 |
脂质缀合抗体
|
|
EP2590997B1
(en)
*
|
2010-07-09 |
2018-04-04 |
Dana-Farber Cancer Institute, Inc. |
Stabilized insulinotropic peptides and methods of use
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
KR101382593B1
(ko)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
EA030886B1
(ru)
|
2010-08-17 |
2018-10-31 |
Амбркс, Инк. |
Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
|
|
WO2012083078A2
(en)
|
2010-12-15 |
2012-06-21 |
The Research Foundation Of State University Of New York |
Croos-linked peptides and proteins, methods of making same, and uses thereof
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
WO2012088379A2
(en)
|
2010-12-22 |
2012-06-28 |
Marcadia Biotech, Inc. |
Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
|
|
US20140213502A1
(en)
|
2011-04-29 |
2014-07-31 |
United States Department of Health and Human Services |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
|
RU2014103288A
(ru)
|
2011-07-01 |
2015-08-10 |
Байер Интеллектчуал Проперти Гмбх |
Слитые полипептиды релаксина и их применение
|
|
KR20140039257A
(ko)
|
2011-07-08 |
2014-04-01 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
릴랙신을 방출하는 융합 단백질 및 이의 용도
|
|
TW201806968A
(zh)
|
2011-10-18 |
2018-03-01 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
KR101895047B1
(ko)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
|
|
EP2819688A4
(en)
|
2012-02-15 |
2015-10-28 |
Aileron Therapeutics Inc |
TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9273093B2
(en)
|
2012-10-11 |
2016-03-01 |
Protagonist Therapeutics, Inc. |
α4β7 peptide dimer antagonists
|
|
WO2014071241A1
(en)
|
2012-11-01 |
2014-05-08 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
AU2014261111B2
(en)
*
|
2013-05-02 |
2017-03-16 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
|
WO2015006744A1
(en)
|
2013-07-11 |
2015-01-15 |
The California Institute For Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
|
JP6822839B2
(ja)
|
2013-09-13 |
2021-01-27 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、及びその組成物
|
|
KR102455171B1
(ko)
*
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
TWI582109B
(zh)
|
2015-01-09 |
2017-05-11 |
美國禮來大藥廠 |
Ｇｉｐ及ｇｌｐ－１共促效劑化合物
|
|
MA41794A
(fr)
|
2015-03-18 |
2018-01-23 |
The California Institute For Biomedical Res |
Agents thérapeutiques modifiés et compositions associées
|
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
US20190216893A1
(en)
|
2016-06-03 |
2019-07-18 |
The Scripps Research Institute |
Compositions and methods of modulating immune response
|
|
JOP20190095A1
(ar)
*
|
2016-10-27 |
2019-04-28 |
Janssen Pharmaceutica Nv |
مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
キメラ抗原受容体の調節
|
|
CA3058953A1
(en)
|
2017-04-05 |
2018-10-11 |
Revolution Medicines, Inc. |
Compounds that participate in cooperative binding and uses thereof
|
|
CA3090417A1
(en)
|
2018-02-23 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
WO2019203645A1
(en)
*
|
2018-04-19 |
2019-10-24 |
Stichting Vu |
Protein macrocyclization
|
|
TWI847981B
(zh)
*
|
2018-04-25 |
2024-07-11 |
比利時商健生藥品公司 |
類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
|
|
KR20240051304A
(ko)
|
2018-07-23 |
2024-04-19 |
일라이 릴리 앤드 캄파니 |
Gip/glp1 공효능제 화합물
|
|
US11691984B2
(en)
|
2018-10-12 |
2023-07-04 |
The Scripps Research Institute |
Compounds and methods for DCAF-mediated protein degradation
|
|
MX2022006861A
(es)
|
2019-12-04 |
2022-07-11 |
Scripps Research Inst |
Agonistas del receptor glp2 y metodos de uso.
|
|
KR20240032010A
(ko)
|
2021-06-09 |
2024-03-08 |
더 스크립스 리서치 인스티튜트 |
장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
|